Cancer Biology

PA28γ promotes the malignant progression of tumor by elevating mitochondrial function via C1QBP

1. Jiongke Wang
2. Yujie Shi
3. Ying Wang
4. Yingqiang Shen
5. Huan Liu
6. Silu Sun
7. Yimei Wang
8. Xikun Zhou
9. Yu Zhou
10. Xin Zeng
11. Jing Li
12. Qianming Chen

• Curated by eLife

  eLife Assessment

  This manuscript determines how PA28g, a proteasome regulator that is overexpressed in tumors, and C1QBP, a mitochondrial protein for maintaining oxidative phosphorylation that plays a role in tumor progression, interact in tumor cells to promote their growth, migration and invasion. Additional experiments and analyses that supported the theoretical models for the interaction have been performed in response to the reviews. The overall findings and conceptual framework are important and the evidence is solid. A logical extrapolation of this work is to test the C1QBP mutants using functional assays to determine whether the mutations can decrease the protein stability mediated by the interaction with PA28g.

Reviewed by eLife

PRMT1-mediated metabolic reprogramming promotes leukemogenesis

1. Hairui Su
2. Yong Sun
3. Han Guo
4. Chiao-Wang Sun
5. Qiuying Chen
6. Szumam Liu
7. Anlun Li
8. Min Gao
9. Rui Zhao
10. Glen Raffel
11. Jian Jin
12. Cheng-Kui Qu
13. Michael Yu
14. Christopher A Klug
15. George Y Zheng
16. Scott Ballinger
17. Matthew Kutny
18. Long X Zheng
19. Zechen Chong
20. Chamara Senevirathne
21. Steven Gross
22. Yabing Chen
23. Minkui Luo
24. Xinyang Zhao

• Curated by eLife

  eLife Assessment

  This study reveals that PRMT1 overexpression drives tumorigenesis of acute megakaryocytic leukemia (AMKL) and that targeting PRMT1 is a viable approach for treating AMKL. After revision, both reviewers found that these findings are important and that the data supporting these findings are convincing. Furthermore, these findings likely have significant implications for the treatment of AMKL with PRMT1 overexpression in the future.

Reviewed by eLife

Reduced mitochondrial transcription sensitizes acute myeloid leukemia cells to BCL-2 inhibition

1. Laleh S Arabanian
2. Jenni Adamsson
3. Anke Unger
4. Raffaella Di Lucrezia
5. Tim Bergbrede
6. Arghavan Ashouri
7. Erik Larsson
8. Peter Nussbaumer
9. Bert M Klebl
10. Lars Palmqvist
11. Claes M Gustafsson

• Curated by eLife

  eLife Assessment

  This solid study assesses a mitochondrial polymerase inhibitor in combination with the BCL-2 inhibitor venetoclax, with the aim to increase the elimination of acute myeloid leukemia. It provides valuable findings of combinatorial efficacy using preclinical models in vitro and in vivo, confirming the overall importance of targeting oxidative phosphorylation to overcome venetoclax resistance in acute myeloid leukemia, and could be strengthened through mechanistic studies demonstrating on target effects and pharmacodynamic efficacy in vivo. The study is of interest to hematologists because it addresses a key biomedical issue in acute myeloid leukemia (venetoclax resistance) and provides data regarding the safety and activity of a novel inhibitor of the mitochondrial polymerase in combination with venetoclax.

Reviewed by eLife

NOLC1 suppresses immunochemotherapy by inhibiting p53-mediated ferroptosis in gastric cancer

1. Shengsheng Zhao
2. Ji Lin
3. Bingzi Zhu
4. Yin Jin
5. Qiantong Dong
6. Xiaojiao Ruan
7. Dan Jin
8. Yongdong Yi
9. Binglong Bai
10. Hongzheng Li
11. Danna Liang
12. Jianhua Lu
13. Letian Meng
14. Xiang Wang
15. Yuekai Cui
16. Yuyang Gu
17. Xian Shen
18. Xufeng Lu
19. Shangrui Rao
20. Weijian Sun

• Curated by eLife

  eLife Assessment

  This fundamental study identified a novel role of NOLC1 in regulating p53 nuclear transcriptional activity and p53-mediated ferroptosis in gastric cancer. After major revisions, the evidence supporting the conclusions is solid. However, some new experiments are needed to draw more robust conclusions regarding the ferroptosis-associated studies.

Reviewed by eLife

Subtype-specific enhancer RNAs define transcriptional regulators and prognosis in breast cancers

1. Aamena Y Patel
2. Peyman Zarrineh
3. Jigar H Sheth
4. Sumitra Mohan
5. Mudassar Iqbal
6. Sankari Nagarajan

Reviewed by Review Commons

Drug-Induced p53 Activation Limits Pancreatic Cancer Initiation

1. Jennifer J Twardowski
2. Thomas I Heist
3. Zamira Guerra Soares
4. Emily S Berry
5. Luis I Ruffolo
6. Christoph Pröschel
7. Stephano S Mello

Reviewed by Review Commons

Single-cell dissection of prognostic architecture and immunotherap response in Helicobacter pylori infection-associated gastric cancer

1. Xin Zhang
2. Guangyu Zhang
3. Shuli Sang
4. Yang Fei
5. Xiaopeng Cao
6. Wenge Song
7. Feide Liu
8. Jinze Che
9. Haoxia Tao
10. Hongwei Wang
11. Lihua Zhang
12. Yiyan Guan
13. Shipeng Rong
14. Lijuan Pei
15. Sheng Yao
16. Yanchun Wang
17. Min Zhang
18. Chunjie Liu

• Curated by eLife

  eLife Assessment

  This study presents a valuable description of the cellular and transcriptional landscape of the tumor microenvironment in 27 gastric cancer (GC) patients based on their H. pylori status (HpGC, ex-HpGC, non-HpGC). The single-cell RNA sequencing dataset and computational analysis are convincing and provide a starting point that is of value for understanding H pylori-associated GC cell type composition, cell transitions, and mechanisms of response to therapy. The section correlating immunotherapy outcomes with GC cell type compositions from bulk RNAseq would have been strengthened by further comparing H. pylori GC versus non H. pylori GC.

Reviewed by eLife

Phosphodiesterase 1A physically interacts with YTHDF2 and reinforces the progression of non-small cell lung cancer

1. Chong Zhang
2. Zuoyan Zhang
3. Yueyi Wu
4. Yuchen Wu
5. Jing Cheng
6. Kaizhi Luo
7. Zhidi Li
8. Manman Zhang
9. Jian Wang
10. Xuesen Zhang
11. Yangling Li

• Curated by eLife

  eLife Assessment

  This manuscript provides valuable mechanistic insight into NSCLC progression, both in terms of tumour metastasis and the development of chemoresistance. The authors draw upon a range of techniques and assays and the evidence shown is solid and has been strengthened by incorporation of suggestions by the two reviewers. The work presented will be of interest to cancer biologists and more broadly to those interested in NSCLC translational studies.

Reviewed by eLife

Inhibition of p38-MK2 pathway enhances the efficacy of microtubule inhibitors in breast cancer cells

1. Yu-Chia Chen
2. Mamoru Takada
3. Aerica Nagornyuk
4. Muhan Yu
5. Hideyuki Yamada
6. Takeshi Nagashima
7. Masayuki Ohtsuka
8. Jennifer G DeLuca
9. Steven M Markus
10. Motoki Takaku
11. Aussie Suzuki

• Curated by eLife

  eLife Assessment

  This study provides valuable findings that MK2 inhibitor CMPD1 can inhibit the growth, migration and invasion of breast cancer cells both in vitro and in vivo. The evidence supporting the claims of the authors is solid, although the detailed molecular mechanism and additional animal experiments would strengthen the paper. This study will be of interest to the breast cancer field.

Reviewed by eLife

Ferroptosis-related genes mediate tumor microenvironment and prognosis in triple-negative breast cancer via integrated RNA-seq analysis

1. Xuantong Gong
2. Lishuang Gu
3. Di Yang
4. Yu He
5. Qian Li
6. Hao Qin
7. Yong Wang

• Curated by eLife

  eLife Assessment

  This study presents a useful finding for the ferroptosis-mediated tumor microenvironment (TME) in triple-negative breast cancer (TNBC) using public single-cell RNA sequencing (scRNA-seq) and bulk RNA sequencing data. The data were collected and analyzed using solid and validated methodology and can be used as a starting point for functional studies of TME in TNBC. The work will be of interest to medical biologists working in the field of TNBC.

Reviewed by eLife